Metis Techbio-P 07666
IPOIPO Allotment Results Analysis
8.36019.69%( -2.050 )
Nov 13 · End-of-day data, not live · Hong Kong Stock Exchange
Allotment Results · Computershare · 20260513
IPOIPO Allotment Results Analysis| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 贝莱德 | 37,304,500 | 3.24% | — | 6 months |
| UBS AM Singapore | 11,191,000 | 0.97% | — | 6 months |
| 国风投创新投资基金股份有限公司 | 7,460,500 | 3.71% | 0.71% | 6 months |
| 未来资产 | 5,968,500 | 2.97% | 2.58% | 6 months |
| HHLRA | 5,968,500 | 2.97% | 2.58% | 6 months |
| Deerfield | 3,730,000 | 1.85% | 1.61% | 6 months |
| RTW基金 | 3,730,000 | 1.85% | 1.61% | 6 months |
| Huadeng Technology | 3,730,000 | 1.85% | 1.61% | 6 months |
| Isometry Global | 3,730,000 | 1.85% | 1.61% | 6 months |
| 广发基金 | 3,730,000 | 1.85% | 1.61% | 6 months |
| 工银瑞信实体 | 3,730,000 | 1.85% | 1.61% | 6 months |
| 华夏基金（香港） | 3,730,000 | 1.85% | 1.61% | 6 months |
| 富国基金 | 3,730,000 | 1.85% | 1.61% | 6 months |
| Lake Bleu | 2,984,000 | 1.48% | 1.29% | 6 months |
| Sage Partners | 2,984,000 | 1.48% | 1.29% | 6 months |
| 工银理财 | 1,492,000 | 0.74% | 0.64% | 6 months |
| ORIX Asia AM | 1,492,000 | 0.74% | 0.64% | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO drew extreme enthusiasm with an oversubscription ratio of 6,910.96x, compressing the overall hit rate to just 17.15%. The Chapter 18C specialist tech status and biopharma sector appeal fueled overwhelming retail demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
At the A-tail (甲尾), applicants received a mere 0.1321 expected lots, while B-head (乙头) allocations reached 0.3638 lots—a 2.8x advantage. This wide gap shows that the top A-tier was heavily crowded, making B-head a notably more allocation-efficient tier in this distribution. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Mainland China participation dominated at 58.9% of successful applicants, signaling strong cross-border appetite for a Chapter 18C biopharma listing. The investor base was 59.5% male, and the expanded holder count of 65,727 indicates broad retail distribution. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Metis Techbio-P (07666): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.
